Last updated: 2026-09-07 15:42:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Janux Therapeutics, Inc. (JANX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $20,23, with a market capitalization of $1,24B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12,12 to $35,34. This page covers its latest market performance, valuation, price trends and company information.
$1,24B | |
$19,62 | |
$71,71 | |
$5,65 | |
$19,80 | |
596,02K | |
1,01M | |
-- | |
$35,34 | |
$12,12 | |
-- | |
-- |
Janux Therapeutics, Inc. (JANX) last closed at $19,80 as of 2026-09-04 23:54:00, unchanged from the previous close of $19,80.
During the latest regular trading session, JANX traded between $5,65 and $71,71, with a volume of 596,02K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Janux Therapeutics, Inc. (JANX) moved from $18,78 to $20,23, representing a gain of 7,73% ($1,45).
The stock traded between $17,66 and $20,31 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 974,47 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 34,9%
JANX is currently trading at $20,23, placing it 34,9% of the way from its 52-week low of $12,12 to its 52-week high of $35,34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 113 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Janux Therapeutics, Inc. (JANX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.